{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-038446","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2026-08-14T20:30:49+00:00","discovered_at":"2026-08-14T20:36:01.490844+00:00","generated_at":"2026-08-14T20:36:19.933549+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"GT Biopharma shareholders approve reverse stock split and incentive plan amendments","bullets":["Approved reverse stock split (1-for-10 to 1-for-30) and cut authorized common to 25M, preferred to 1.5M.","Elected directors Breen, Casamento, Kramer, Mun-Gavin; votes ranged 6.7M-8.1M for.","Ratified Weinberg & Company as independent auditor for FY2026 (22.7M for).","Approved non-binding executive compensation (6.1M for) and 2022 Plan amendments adding 3.5M shares and evergreen provision."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-038446","json":"https://secwatch.observer/filing/0001493152-26-038446.json","markdown":"https://secwatch.observer/filing/0001493152-26-038446.md","text":"https://secwatch.observer/filing/0001493152-26-038446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000149315226038446/0001493152-26-038446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000149315226038446/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T20:36:19.933549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}